0 Items
Select Page

Japanese Encephalitis

Japanese encephalitis virus (JEV) is the most significant cause of viral encephalitis in Asia. It is a mosquito-borne flavivirus belonging to the same genus as the Dengue, Yellow Fever and West Nile viruses. The annual incidence of clinical disease varies both across and within endemic countries, ranging from <1 to >10 per 100,000 people or higher during outbreaks. JEV primarily affects children as adults in endemic countries have natural immunity after a childhood infection, though individuals of any age may be affected.

The Native Antigen company develop mammalian-expressed recombinant JEV NS1 proteins and highly-specific monoclonal antibodies that show no cross-reactivity with other flaviviruses.

Japanese Encephalitis Background

The Japanese encephalitis virus belongs to the genus Flavivirus, of the family Flaviviridae. JEV is also a member of the Japanese encephalitis serology complex, which includes West Nile, St. Louis encephalitis and Murray Valley encephalitis virus. In nature, JEV cycles primarily between water birds and mosquitoes of the Culex species, but pigs can also be infected and act as amplifying hosts. JEV can also be transmitted to incidental hosts, including humans, horses and other mammals.

In Asia, Japanese encephalitis is the leading cause of viral encephalitis in children, with up to 70,000 cases reported annually. In most cases, JEV infection causes mild symptoms, but a small number of cases develop into severe life-threatening encephalitis. The symptoms of JEV infection are like those seen in other conditions that cause severe encephalitis syndrome. In cases presenting with severe encephalitis, mortality rates can be as high as 30%, with survivors developing long term neurological and behavioural complications. Currently, there is no specific antiviral therapy for JEV, though safe and effective licenced vaccines are available (1).

Diagnosis of JEV infection is achieved by serological testing for JEV specific IgM antibodies in the patient’s cerebrospinal fluid or serum. However, cross-reactivity of JEV specific antibodies with other Flaviviruses that co-circulate with JEV, such as Dengue virus, can be a challenge and can prevent accurate diagnosis (2).

References

  1. WHO Japanese encephalitis Factsheet
  2. Johnson, B.W. et.al. (2016). Differential Diagnosis of Japanese Encephalitis Virus Infections with the Inbios JE Detect™ and DEN Detect™ MAC-ELISA Kits. Am. J. Trop. Med. Hyg. 94: 820–828.

Japanese Encephalitis Antigens

The Native Antigen Company prepares recombinant JEV NS1 and Envelope proteins in a proprietary mammalian cell expression system to generates highly pure proteins. Our Japanese Encephalitis virus antigens are properly glycosylated and folded.  The JEV NS1 protein is presented in a predominantly hexameric form.

Japanese Encephalitis Antibodies

We have used our recombinant JEV NS1 proteins to raise a panel of specific antibodies to JEV NS1, all of which are highly specific and show no cross-reactivity with NS1 proteins from other flaviviruses, including Dengue, Yellow Fever and West Nile viruses.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Using Adenoviruses to Fight Cancer

In the second of a 2-part series, we discuss how adenoviruses are being developed to treat cancer and some of the hurdles these platforms face from our own immune systems. Curing cancer is one of the biggest challenges of the 21st century. Our knowledge of cancer’s...

New Immunofluorescence Data for our CMV, Yellow Fever and Ebola Antibodies

In September 2018 The Native Antigen Company and Virology Research Services (VRS) were awarded the Medical Research Council (Proximity to Discovery Award for Knowledge Exchange) to test a large panel of our viral antibodies in immunofluorescence applications. This...

Why are ticks such good vectors of pathogens?

In this blog, Professor Patricia Nuttall discusses what makes ticks such effective vectors of pathogens and how we might prevent the spread of tick-borne diseases. About Patrica Nuttall Pat Nuttall is Emeritus Professor of Arbovirology in the Department of Zoology,...

Dengue in 2019

What's going on with dengue? Dengue virus (DENV) has been in the news a lot recently. The number of reported cases continues to climb year-on-year and 2019 has been especially bad. Rio de Janeiro has seen a 45% increase in dengue cases in the first two months of 2019...

Zika Prevalence in Suriname – an insight into assay cross-reactivity

A recent study published by Langerak et al tested for the seroprevalence of Zika virus in Suriname populations and evaluated the comparative effectiveness of using a commercial ELISA and a standard Virus Neutralisation Assay. Here we discuss the study, its results,...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

1 + 13 =

Live Customer Feedback